Inspire Medical reports Q4 revenue ~$239.7M (+25% YoY); issues 2025 guidance $940-955M

Inspire Medical Systems, Inc.

2024-FY EPS reported $1.75 revenue$802,804,000

Preliminary Q4 2024 revenue ~$239.5-239.7M, up 25% YoY; full year 2024 revenue ~$802.6-802.8M, up 28% YoY.
Initial FY2025 revenue guidance of $940-955M, representing 17-19% growth over FY2024.
Soft launch of Inspire V neurostimulator with over 40 implants completed in Singapore and U.S.
Appointed Jason Kelly as Chief Manufacturing and Quality Officer effective Jan 20, 2025; Dr. Sparks, CMO, left.
Activated 72 new U.S. centers in Q4 (total 1,435); 12 new sales territories (total 335).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.